Medical Science
| Open Access |
DOI: Role Of Fetuin-A In The Clinical And Laboratory Manifestations Of Calcification In Chronic Kidney Disease
Yuldoshev Turgun Ravshanovich , Termiz Branch of Tashkent State Medical University, Uzbekistan Sabirov Maksud Atabaevich , Republican Center of Specialized Nephrology and Kidney Transplantation Scientific and Practical Medicine, Uzbekistan Munavvarov Burkhan Abdujalilovich , Tashkent State Medical University, UzbekistanAbstract
The article presents the results of a study on changes in calcium-phosphorus balance in patients with chronic kidney disease, depending on the level of fetuin-A in the blood serum, and on the calcification processes that occur in the body. It also discusses changes in calcium, phosphorus, PTH, and vitamin D, as well as the occurrence of cardiac calcification, in the study groups with normal and low levels of fetuin-A. The conclusions based on the conducted studies also recognize the promising research that needs to be done in this regard.
Keywords
Chronic kidney disease, fetuin-A, calcium
References
Esayan A.M. i dr. Prevalence of chronic kidney disease among patients, obrativshikhsya v uchrejdeniya primary medical-sanitary assistant. резолаты проспективного наблюдательного issledovaniya v 12 regionax Rossii // Nephrology (volume 13) No. 3. 2021. S 6 - 16. DOI : https://dx.doi.org/10.18565/nephrology.2021.3.6-16
Isirgapova S.N. and head q. Effect of blood electrolyte disturbances on quality of life in young climacteric patients of SBK stage 5. // Scientific report , educational , spiritual journal of Tibbiyotdayangi Kun . Bukhara. - 2023. - No. 8. - Pages 90-98 .
Isirgapova S.N. i dr. Disturbance of mineral exchange in patients with climacteric syndrome receiving programmatic hemodialysis and ego correction // Materialy kongressa natsionalnogo pochechnogo fonda respubliki Kazakhstan: "VAJNAYa VEXA: konceptualnye pokhody i klyuchevye napravleniya mnogogrannoy nephrologii" Kazakhstan. Almaty. - 2022- S. 24-25.
Makhieva A.T. i dr. Fetuin A is a marker for early risk development of mineralo-osteoarthritis and cardiac-vascular formation. calcification in patients with chronic lung disease 5 - stage. Nephrology . 2022;26(4):105-109. https://doi.org/10.36485/1561-6274-2022-26-4-105-109
Papichev E.V. i dr. Fetuin-A. novyy hepatokin and diagnosis of rheumatoid arthritis. Clinical laboratory diagnostics. 2018; 63 (12): 756-760. DOI: http://dx.doi.org/10.18821/0869-2084-2018-63-12-756-760
Harman H. et al. Comparison of fetuin-A and transforming growth factor beta 1 levels in patients with spondyloarthropathies and rheumatoid arthritis. Int J Rheum Dis. 2016;20(12):2020-7. doi: 10/1111/1756-185X.12791.
Mihai S. et al. (2016). Proteomic biomarkers panel: new insights in chronic kidney disease. Dis . Markers 2016:3185232. doi : 10.1155/2016/3185232
Ozturk S. et al. Fetuin-A and its association with disease activity on psoriatic arthritis. Ann Rheum Dis. 2014;73:207. doi: 10.1136/annrheumdis-2014-eular.4473.
Pal D. et al. (20 2 2). Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat . Med . 18, 1279–1285. doi : 10.1038/nm.2851 .
Pedro Magalhães et al. Urinary fetuin-A peptides as a new marker for impaired kidney function in patients with type 2 diabetes, Clinical Kidney Journal, 2020, sfaa176.
Pedro Magalhães et al. Urinary fetuin-A peptides as a new marker for impaired kidney function in patients with type 2 diabetes, Clinical Kidney Journal, 2020, sfaa176.
Zhou Z. et al. (2019) Circulating Fetuin-A and Risk of All-Cause Mortality in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Front . Physiol . 10:966. https://doi.org/10.3389/fphys.2019.00966
Download and View Statistics
Copyright License
Copyright (c) 2026 Yuldoshev Turgun Ravshanovich, Sabirov Maksud Atabaevich, Munavvarov Burkhan Abdujalilovich
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.